1,672
23
Essay, 2 pages (300 words)

Corrigendum: dual-mtor inhibitor rapalink-1 reduces prostate cancer patient-derived xenograft growth and alters tumor heterogeneity

A Corrigendum on

By La Manna F, De Menna M, Patel N, Karkampouna S, De Filippo MR, Klima I, Kloen P, Beimers L, Thalmann GN, Pelger RCM, Jacinto E and Kruithof-de Julio M (2020). Front. Oncol. 10: 1012. doi:

An author name was incorrectly spelled as “ Maria De Filippo”. The correct spelling is “ Maria Rosaria De Filippo”.

In the published article, there was also an error in affiliation 1. Instead of “ Department of BioMedical Research, University of Bern, Bern, Switzerland”, it should be “ Department for BioMedical Research, Urology Research Laboratory, University of Bern, Bern, Switzerland”.

There was also an error in the text. The concentration and administration schedule of Rapalink-1 reported for the in vivo experiment was not correct. The error appeared both in the “ Materials and Methods” and in the “ Results” sections, where it is incorrectly reported as “ 1. 5 mg/g [ … ] every 5 days” and “ 1. 5 mg/g/6 days”, respectively. Figure 5C in the original article reported the correct administration schedule.

A correction has been made to the “ Materials and Methods” section, “ Animals Maintenance and in vivo Experiment” sub-section:

“ Group 1 received 3. 5 μl/g of vehicle (20% DMSO, 40% PEG-300 and 40% PBS) i. p. once a week while group 2 received Rapalink-1 (1. 5 mg/Kg) resuspended in vehicle, i. p. every 5-7 days.”

A correction of the same error has been made to the “ Results” section, “ Treatment of LAPC9 in vivo With Rapalink-1 Delays Tumor Growth” sub-section, paragraph 2:

“ We then assessed the effect of Rapalink-1 (1. 5 mg/Kg/5-7 days) in vivo on LAPC9 PDX model, comparing the treatment to vehicle only, a schematic of treatment schedule is reported (Figure 5C).”

The authors apologize for these errors and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.

Thank's for Your Vote!
Corrigendum: dual-mtor inhibitor rapalink-1 reduces prostate cancer patient-derived xenograft growth and alters tumor heterogeneity. Page 1
Corrigendum: dual-mtor inhibitor rapalink-1 reduces prostate cancer patient-derived xenograft growth and alters tumor heterogeneity. Page 2
Corrigendum: dual-mtor inhibitor rapalink-1 reduces prostate cancer patient-derived xenograft growth and alters tumor heterogeneity. Page 3

This work, titled "Corrigendum: dual-mtor inhibitor rapalink-1 reduces prostate cancer patient-derived xenograft growth and alters tumor heterogeneity" was written and willingly shared by a fellow student. This sample can be utilized as a research and reference resource to aid in the writing of your own work. Any use of the work that does not include an appropriate citation is banned.

If you are the owner of this work and don’t want it to be published on AssignBuster, request its removal.

Request Removal
Cite this Essay

References

AssignBuster. (2021) 'Corrigendum: dual-mtor inhibitor rapalink-1 reduces prostate cancer patient-derived xenograft growth and alters tumor heterogeneity'. 23 December.

Reference

AssignBuster. (2021, December 23). Corrigendum: dual-mtor inhibitor rapalink-1 reduces prostate cancer patient-derived xenograft growth and alters tumor heterogeneity. Retrieved from https://assignbuster.com/corrigendum-dual-mtor-inhibitor-rapalink-1-reduces-prostate-cancer-patient-derived-xenograft-growth-and-alters-tumor-heterogeneity/

References

AssignBuster. 2021. "Corrigendum: dual-mtor inhibitor rapalink-1 reduces prostate cancer patient-derived xenograft growth and alters tumor heterogeneity." December 23, 2021. https://assignbuster.com/corrigendum-dual-mtor-inhibitor-rapalink-1-reduces-prostate-cancer-patient-derived-xenograft-growth-and-alters-tumor-heterogeneity/.

1. AssignBuster. "Corrigendum: dual-mtor inhibitor rapalink-1 reduces prostate cancer patient-derived xenograft growth and alters tumor heterogeneity." December 23, 2021. https://assignbuster.com/corrigendum-dual-mtor-inhibitor-rapalink-1-reduces-prostate-cancer-patient-derived-xenograft-growth-and-alters-tumor-heterogeneity/.


Bibliography


AssignBuster. "Corrigendum: dual-mtor inhibitor rapalink-1 reduces prostate cancer patient-derived xenograft growth and alters tumor heterogeneity." December 23, 2021. https://assignbuster.com/corrigendum-dual-mtor-inhibitor-rapalink-1-reduces-prostate-cancer-patient-derived-xenograft-growth-and-alters-tumor-heterogeneity/.

Work Cited

"Corrigendum: dual-mtor inhibitor rapalink-1 reduces prostate cancer patient-derived xenograft growth and alters tumor heterogeneity." AssignBuster, 23 Dec. 2021, assignbuster.com/corrigendum-dual-mtor-inhibitor-rapalink-1-reduces-prostate-cancer-patient-derived-xenograft-growth-and-alters-tumor-heterogeneity/.

Get in Touch

Please, let us know if you have any ideas on improving Corrigendum: dual-mtor inhibitor rapalink-1 reduces prostate cancer patient-derived xenograft growth and alters tumor heterogeneity, or our service. We will be happy to hear what you think: [email protected]